What the updated dyslipidemia cholesterol guideline means for your patients at cardiovascular risk

This webinar is on-demand and can be viewed at your convenience.

Cardiovascular risk assessment is evolving, with the 2026 ACC/AHA Dyslipidemia Guideline now recommending that every adult have lipoprotein(a) — Lp(a), an inherited cardiovascular risk factor — measured at least once in a lifetime.

The 2026 American College of Cardiology/American Heart Association Guideline on the Management of Dyslipidemia includes updated recommendations with direct implications for how clinicians identify, measure and treat patients at elevated cardiovascular risk.

This on-demand session, featuring two physician leaders from Boston University School of Medicine, unpacks those updates with clarity and clinical context. Donald Lloyd-Jones, MD — guideline writing committee member, past AHA president, and principal investigator of the Framingham Heart Study — is joined by Frank Qian, MD, clinical instructor, to walk through what clinicians across specialties need to know.

Insights include:

How Lp(a) contributes to CVD risk and why it's now a more prominent focus in updated guidelines
What the updated Lp(a) measurement recommendations mean for clinical practice
How the PREVENT-atherosclerotic CVD equations guide lipid-lowering therapy decisions
A practical overview of lipid treatment goals

Presenters:

Donald M. Lloyd-Jones, MD, ScM, FAHA, FACC

Alexander Graham Bell Professor, Director of the Framingham Center for Population and Prevention Science, PI of the Framingham Heart Study, and Section Chief of Preventive Medicine and Epidemiology in the Department of Medicine Boston University School of Medicine